Medical Center. The meeting will be held on Friday, March 19, 2010, at the National Institutes of Health, Building 31, 31 Center Drive, Floor 6C, Room 6, Bethesda, MD 20892, from approximately 8:30 a.m. to 2 p.m.

This meeting is the second in a series of public meetings with the National Research Council to review the ongoing supplementary risk assessment study. It was originally scheduled to take place on February 12, 2010, but had to be postponed due to extreme weather conditions on the East Coast.

Signup for public comment will begin at approximately 8 a.m. In the event that time does not allow for all those interested in presenting oral comments, anyone may file written comments using the following address below.

An agenda and slides for the meeting may be obtained prior to the meeting by connecting to *http://nihblueribbonpanel-bumc-neidl.od.nih.gov/*. For additional information concerning this meeting, please contact Ms. Laurie Lewallen, Advisory Committee Coordinator, Office of Biotechnology Activities, Office of Science Policy, Office of the Director, National Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892–7985; telephone 301–496–9838; e-mail *lewallenl@od.nih.gov*.

Dated: March 1, 2010.

Amy P. Patterson,

Director, Office of Biotechnology Activities, National Institutes of Health.

[FR Doc. 2010–4724 Filed 3–4–10; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Deafness and Other Communication Disorders; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Board of Scientific Counselors, NIDCD.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors, NIDCD.

Date: March 26, 2010.

Open: 7:30 a.m. to 8 a.m.

Agenda: Reports from institute staff.

Place: National Institutes of Health, Natcher Building, 45 Center Drive, Room F1/F2, Bethesda, MD 20892.

Closed: 8 a.m. to 4:30 p.m.

Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators.

Place: National Institutes of Health, Natcher Building, 45 Center Drive, Room F1/F2, Bethesda, MD 20892.

Contact Person: Andrew J. Griffith, Ph.D., MD., Director, Division of Intramural Research, National Institute on Deafness and Other Communication Disorders, 5 Research Court, Room 1A13, Rockville, MD 20850, 301–496–1960, *griffita@nidcd.nih.gov*.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.173, Biological Research Related to Deafness and Communicative Disorders, National Institutes of Health, HHS)

Dated: March 1, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010–4767 Filed 3–4–10; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2010–N–0054]

Strengthening the Center for Devices and Radiological Health's 510(k) Review Process; Public Meeting; Extension of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; extension of comment period.

SUMMARY: The Food and Drug Administration (FDA) is extending to March 19, 2010, the comment period for the notice that appeared in the **Federal Register** of Wednesday, January 27, 2010 (75 FR 4402). In the notice, FDA requested comments on a number of identified challenges associated with the 510(k) process. The agency is taking this action to allow interested persons additional time to submit comments.

DATES: Submit written or electronic comments and information by March 19, 2010.

ADDRESSES: Submit written comments or information to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments or information to *http://www.regulations.gov*. Identify comments with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: James Swink, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 1609, Silver Spring, MD 20993, 301–796–6313, e-mail: *james.swink@fda.hhs.gov*.

SUPPLEMENTARY INFORMATION:

I. Background

In the **Federal Register** of January 27, 2010 (75 FR 4402), FDA published a notice announcing a public meeting on February 18, 2010, and the opening of a public docket to receive comments on key challenges related to the premarket notification (or 510(k)) process for the review of medical devices. Specific questions for comment were listed and interested persons were invited to submit comments by March 5, 2010. At this time, the agency is extending the comment period until March 19, 2010, to continue to receive public comments. Comments submitted to the docket will assist in identifying actions that the Center for Devices and Radiological Health can consider taking to strengthen the 510(k) process.

II. Submission of Comments

Interested persons may submit to the Division of Dockets Management (see **ADDRESSES**) written or electronic comments regarding this document. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. All comments submitted to the public docket are public information and may be posted to FDA's Web site at *http://www.fda.gov* for public viewing. Comments are to be identified with the docket number found in brackets in the heading of this document. In addition,